(E)-3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-4,5,6,7-tetrahydro-benzofuran-2-yl]-acrylic acid | 503620-39-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-4,5,6,7-tetrahydro-benzofuran-2-yl]-acrylic acid
• 英文别名: 2-Propenoic acid, 3-(4,5,6,7-tetrahydro-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-benzofuranyl)-；(E)-3-[4-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-4,5,6,7-tetrahydro-1-benzofuran-2-yl]prop-2-enoic acid
• CAS: 503620-39-1
• 化学式: C₂₅H₃₀O₃
• 分子量: 378.511
• InChiKey: WRWCAQNPEXYGJK-PKNBQFBNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6,7-二氢-4(5H)-苯并呋喃酮 在 lithium hydroxide 、 sodium tetrahydroborate 、 正丁基锂 、 三氟化硼乙醚 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙二醇二甲醚 、 正己烷 为溶剂， 反应 2.17h， 生成 (E)-3-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-4,5,6,7-tetrahydro-benzofuran-2-yl]-acrylic acid
  参考文献：
  名称：

  Structure-Based Design of Potent Retinoid X Receptor α Agonists

  摘要：

  A series of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids that showed potent agonist activity against RXRalpha were synthesized via a structure-based design approach. Among the compounds studied, 46a,b showed not only very good potency against RXRalpha (K(i) = 6 nM) but was also found to be greater than 167-fold selective vs RARalpha (K(i) > 1000 nM). This compound profiled out as a full agonist in a cell-based transient transfection assay (EC(50) = 3 nM). The two antipodes were separated via chiral chromatography, and 46b was found to be 40-fold more potent than 46a. Interestingly, cocrystallization of 46a,b with the RXRalpha protein generated a liganded structure whereby the (S)-antipode was found in the binding pocket. Given orally in db/db mice or ZDF rats, 46a,b showed a significant glucose-lowering effect and an increase in liver mass. Triglycerides decreased significantly in db/db mice but increased in the ZDF rats. A dose-dependent decrease of nonesterified free fatty acids was seen in ZDF rats but not in db/db mice. These differences indicate a species specific effect of RXR agonists on lipid metabolism.

  DOI：

  10.1021/jm030565g

文献信息

• Selective rxr ligands
  申请人：——

  公开号：US20040198980A1

  公开（公告）日：2004-10-07

  The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR&agr;, RXR&bgr;, or RXR&ggr;. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

  本发明涵盖了新型视黄醇化合物，其在RXR的一个或多个亚型上具有选择性作为RXR激动剂，目前包括RXRα、RXRβ或RXRγ。因此，本化合物及包含这些化合物的药物组合物在治疗由RXR介导的疾病方面是有效的。除其他生理反应外，本发明的化合物可降低血糖并维持体重，因此对于治疗糖尿病（NIDDIM）和肥胖症是有用的。
• SELECTIVE RXR LIGANDS
  申请人：HAFFNER Dale Curt

  公开号：US20070099991A1

  公开（公告）日：2007-05-03

  The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXRα, RXRβ, or RXRγ. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.

  本发明包括新型视黄醇类化合物，其具有对RXRα、RXRβ或RXRγ中一种或多种同工型具有选择性的RXR激动剂。因此，本化合物及包含这些化合物的制药组合物在治疗由RXR介导的疾病方面是有效的。除了其他生理反应外，本发明的化合物可以降低血糖并维持体重，因此，对于治疗糖尿病（NIDDIM）和肥胖症是有用的。
• BICYCLIC HETEROCYCLES AS RXR LIGANDS
  申请人：SmithKline Beecham Corporation

  公开号：EP1430042A2

  公开（公告）日：2004-06-23
• THERAPEUTIC METHODS
  申请人：Arizona Board of Regents on Behalf of Arizona State University

  公开号：US20160338981A1

  公开（公告）日：2016-11-24

  The invention provides a method for a disease or condition associated with dopamine deficiency (e.g. depression, schizophrenia, or Parkinson's disease) in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal.
• US7173134B2
  申请人：——

  公开号：US7173134B2

  公开（公告）日：2007-02-06